Schizophrenia News

The FDA has accepted the New Drug Application for Indivior’s RBP-7000, a once-monthly, sustained release, injectable risperidone in the Atrigel delivery system, for the treatment of schizophrenia, according to a press release.

Deficits in auditory stimuli inhibition are associated with core pathological features of schizophrenia, supporting the idea that P50 inhibitory processing may guide the development of that target impairments in schizophrenia, according to recent findings.

Results from a 17-site, international incidence study confirm marked heterogeneity in risk for psychotic disorders by person and place, such as higher rates in younger men, racial/ethnic minorities and areas characterized by a lower percentage of owner-occupied homes.

Recent findings indicated a strong association between substance-induced psychosis and conversion to schizophrenia and bipolar disorder, suggesting a need for long-term follow-up to identify most cases.

Psychotic symptoms were associated with later hospitalization for nonaffective psychotic disorders among Israeli military members aged 18 to 21 years; however, symptoms had low predictive value.

Nonaffective psychoses were more common among individuals living in economically deprived and socially isolated rural areas, according to recent findings.

Avatar therapy decreased the severity of persistent auditory verbal hallucinations among individuals with schizophrenia or affective disorders and was more effective than supportive counseling alone.

Recent findings indicated a polygenic risk gradient across schizophrenia and bipolar disorder, which was associated with the presence and severity of mood-incongruent psychotic symptoms.

Intra-Cellular Therapies Inc. recently announced the FDA granted fast track designation for lumateperone for treatment of schizophrenia.

The FDA recently accepted for filing a New Drug Application for aripiprazole lauroxil NanoCrystal Dispersion, an investigational product designed for initiation to Aristada extended-release injectable suspension, for treatment of schizophrenia, according to a release from Alkermes.